Publication | Closed Access

Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patients

OncologyHepatologyPhase I/ii StudyMedicinePharmacotherapyLiver CancerCancer TreatmentEast Asian PatientsPharmacologyRadiation OncologyHepatocellular CarcinomaAdvanced Hepatocellular Carcinoma